Avicanna Reveals New CFO Appointment
Leadership Change: Avicanna Inc. has appointed Nick Hilborn as Interim Chief Financial Officer, succeeding Phillip Cardella, who will transition to a consulting role effective September 15, 2025.
Company Overview: Avicanna is a biopharmaceutical company focused on developing and commercializing plant-derived cannabinoid-based products, with a diverse range of proprietary products and a strong emphasis on research and development.
Product Offerings: The company offers a variety of cannabinoid-based products through its RHO Phyto™ brand and operates a medical cannabis care platform, MyMedi.ca, aimed at enhancing patient support and education.
Pharmaceutical Pipeline: Avicanna is developing a pipeline of proprietary cannabinoid-based candidates targeting unmet medical needs in areas such as dermatology, chronic pain, and neurological disorders, supported by its subsidiary's supply of active pharmaceutical ingredients.
About the author









